Newly Diagnosed with Alzheimer’s? A Guide to Your Treatment Options, Risks and Costs
An early Alzheimer’s diagnosis brings important decisions. Learn about Leqembi, IQLIK, and Kisunla, including how they work, treatment schedules, ARIA risks, MRI monitoring, and Medicare costs. Use this guide to prepare for an informed discussion with your neurologist.
ARIA Risk, APOE4 and Alzheimer’s Treatment Explained
When I was diagnosed with Alzheimer’s and learned that APOE could affect my risk of ARIA, I realized I didn't understand the difference between a gene, an allele, and a protein. This is the story of what I learned; what ARIA is; how to understand an APOE genetic blood test, what the risks are and how the risk is monitored.
How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.